Key result
The ADRB1 Arg389Arg and ADRA2C deletion carrier genotype combination was associated with a significantly higher final ejection fraction in heart failure patients treated with metoprolol.
Why the study?
Do ADRB1 and ADRA2C polymorphisms synergistically influence the ejection fraction response to metoprolol therapy in beta-blocker naive heart failure patients?
Population
54 beta-blocker naive heart failure patients
Comparison
Metoprolol CR/XL therapy for 5-6 months in… vs Patients with other genotype combinations…
Design
Cohort
Follow-up
5-6 months
Authors
Loading...
Does not support genotype-guided metoprolol changes in HF; leaves open need for prospective validation.
Cohort (n=54)
Do ADRB1 and ADRA2C polymorphisms synergistically influence the ejection fraction response to metoprolol therapy in beta-blocker naive heart failure patients?
The combination of ADRB1 Arg389Arg and ADRA2C deletion carrier genotypes predicts a significantly greater improvement in left ventricular ejection fraction in heart failure patients treated with metoprolol.
Lobmeyer et al. (2007) conducted a cohort in heart failure (n=54). ADRB1 Arg389Arg and ADRA2C deletion carrier genotypes vs. Other genotype combinations was evaluated on change in left-ventricular ejection fraction. The ADRB1 Arg389Arg and ADRA2C deletion carrier genotype combination was associated with a significantly higher final ejection fraction in heart failure patients treated with metoprolol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: